ProfileGDS5678 / 1440974_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 64% 69% 64% 64% 63% 63% 66% 65% 60% 63% 62% 64% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7037861
GSM967853U87-EV human glioblastoma xenograft - Control 23.8444164
GSM967854U87-EV human glioblastoma xenograft - Control 34.3066769
GSM967855U87-EV human glioblastoma xenograft - Control 43.8208564
GSM967856U87-EV human glioblastoma xenograft - Control 53.8044164
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8231463
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8511863
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9672266
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9246865
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5863360
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7670563
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6609662
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8415264
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8328164